LEUKEMOGENESIS BY TRANSACTIVATING RETROVIRUSES (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

LEUKEMOGENESIS BY TRANSACTIVATING RETROVIRUSES (MEETING ABSTRACT)

Seventh International Symposium on Cancer Research of the House of the Hungarian Academy of Sciences: Convergences of International Cancer Research. June 12-14, 1991, Budapest, Hungary, p. 14, 1991.. Unique Identifier : AIDSLINE ICDB/92679643
Burny A; Kettmann R; Willems L; Portetelle D; Voneche V; Callebaut I; van den Broeke A; Mammerickx M; Mornon JP; Brasseur R; Faculty of Agronomy, GEMBLOUX, Belgium

Abstract: Bovine leukemia virus induces malignant lymphoma in cattle and sheep. In the latter species, 100% of infected animals die in the tumor phase of the disease with a latency inversely correlated to the virus load of the inoculum. Tumor onset is less frequent in infected cattle, due in part to the short economic life-span of domestic animals. The viral information is either silent in the tumor cell or expressed in a very small number of cells, suggesting that repression of the virus is the rule and can only be overcome by a rare set of conditions prevailing in the microenvironment. Virus expression is under the control of a series of transcription factors among which an analog of the CREB-2 protein and the transactivator p34tax play an important role. P34tax does not bind to DNA; its transactivating activity resides in a leucine-rich 40 amino acid segment located in the middle of the molecule. Molecular modeling intending to understand the lipid-protein interaction in the processes of virus entry and syncytia induction lead to the suggestive evidence that oblique insertion of the fusion peptide in the peptide in the lipid bilayer of the target cell is a major factor contributing to virus-cell or cell-cell infusion. The hydrophobic cluster analysis method together with gp51 dissection with monoclonal antibodies provide substantial progress in the understanding of the secondary structure of the protein and the exposure of reactive sites to the humoral immune response.

Keywords: Animal Antibodies, Monoclonal Antibody Formation Cattle Cell Fusion/GENETICS *Gene Expression Gene Products, tax/*GENETICS Giant Cells Leukemia Virus, Bovine/*GENETICS/IMMUNOLOGY Leukemia, Experimental/*GENETICS Sheep Transcription Factors/GENETICS Viral Fusion Proteins/GENETICS ABSTRACT
920430
M9240936

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .